<DOC>
	<DOCNO>NCT02488980</DOCNO>
	<brief_summary>This placebo control , randomise , double-blind , double-dummy study efficacy weekly tafenoquine compare weekly mefloquine placebo chemosuppression P. falciparum Nyanza Province , western Kenya .</brief_summary>
	<brief_title>An Evaluation Weekly Tafenoquine</brief_title>
	<detailed_description>Subjects treat 3 day halofantrine clear exist parasitaemia . At end clearance period , subject free malaria parasitaemia randomize receive load dose study treatment ( tafenoquine 200 mg , Mefloquine 250 mg placebo ) tree day , follow study treatment ( tafenoquine 200 mg , mefloquine 250 mg placebo , respectively ) week 24 week . After treatment period subject attend weekly follow-up safety visit week 28 .</detailed_description>
	<mesh_term>Parasitemia</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<mesh_term>Tafenoquine</mesh_term>
	<criteria>Healthy male female volunteer provide informed consent ( healthy volunteer define one free ailment might cause difficulty evaluate drug efficacy adverse experience ) . Subjects age 1855 year . Subjects plan reside study area entire study duration approximately 70 week Subjects positive parasitaemia follow halofantrine treatment radical cure . Subjects medical condition , opinion investigator , make subject unsuitable enter study . Subjects personal family history seizure . Female subject positive serum betaHCG5 ( test screening within 48 hour first drug administration approximately monthly thereafter ) . Women pregnant lactate opinion investigator risk become pregnant . Subjects clinically significant abnormality ( include limit abnormal hepatic renal function ) determine history , physical routine blood chemistry haematology value . Subjects demonstrate hypersensitivity study drug especially 8aminoquinolines . Subjects unwilling report drug administration blood draw 70 week duration study . Subjects G6PD deficiency . Subjects laboratory guideline value exclusion : haemoglobin &lt; 10 gm/dL , platelet &lt; 80,000/mm3 , WBC &lt; 3000ul3 , creatinine ALT twice upper limit normal age . Subjects abnormal ECG , particularly extend QTc interval &gt; 0.42 second . Subjects take antimalarial product , take antimalarial drug halofantrine within previous two week . Subjects receive investigational drug ( new chemical entity register use ) within 30 day 5 halflives whichever longer . Subjects history psychiatric disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Falciparum Parasitaemia , Malaria</keyword>
</DOC>